ABL001 – a new BCR-ABL inhibitor for chronic myeloid leukemia (CML) treatment
Providing novel treatments and standardising CLL biomarker testing across the world
Results of the Phase III DASISION trial and the future of CML treatment
Novel adoptive transfer mouse models in CLL
Elisa ten Hacken
Inherited and acquired genetic factors involved in the development of CLL
John Gribben et al.